DK0888127T3 - Kombinationer med immunoundertrykkende virkninger indeholdende cyclooxygenase-2-inhibitorer og 5-lipooxygenaseinhibitortorer - Google Patents

Kombinationer med immunoundertrykkende virkninger indeholdende cyclooxygenase-2-inhibitorer og 5-lipooxygenaseinhibitortorer

Info

Publication number
DK0888127T3
DK0888127T3 DK97904133T DK97904133T DK0888127T3 DK 0888127 T3 DK0888127 T3 DK 0888127T3 DK 97904133 T DK97904133 T DK 97904133T DK 97904133 T DK97904133 T DK 97904133T DK 0888127 T3 DK0888127 T3 DK 0888127T3
Authority
DK
Denmark
Prior art keywords
inhibitors
combinations
cyclooxygenase
lipooxygenase
immunosuppressive effects
Prior art date
Application number
DK97904133T
Other languages
English (en)
Inventor
Susan A Gregory
Peter C Isakson
Gary Anderson
Original Assignee
Searle & Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Searle & Co filed Critical Searle & Co
Application granted granted Critical
Publication of DK0888127T3 publication Critical patent/DK0888127T3/da

Links

Classifications

    • H—ELECTRICITY
    • H01—ELECTRIC ELEMENTS
    • H01M—PROCESSES OR MEANS, e.g. BATTERIES, FOR THE DIRECT CONVERSION OF CHEMICAL ENERGY INTO ELECTRICAL ENERGY
    • H01M4/00—Electrodes
    • H01M4/02—Electrodes composed of, or comprising, active material
    • H01M4/24—Electrodes for alkaline accumulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • H—ELECTRICITY
    • H01—ELECTRIC ELEMENTS
    • H01M—PROCESSES OR MEANS, e.g. BATTERIES, FOR THE DIRECT CONVERSION OF CHEMICAL ENERGY INTO ELECTRICAL ENERGY
    • H01M4/00—Electrodes
    • H01M4/02—Electrodes composed of, or comprising, active material
    • H01M4/24—Electrodes for alkaline accumulators
    • H01M4/26—Processes of manufacture
    • H—ELECTRICITY
    • H01—ELECTRIC ELEMENTS
    • H01M—PROCESSES OR MEANS, e.g. BATTERIES, FOR THE DIRECT CONVERSION OF CHEMICAL ENERGY INTO ELECTRICAL ENERGY
    • H01M4/00—Electrodes
    • H01M4/02—Electrodes composed of, or comprising, active material
    • H01M4/64—Carriers or collectors
    • H01M4/70—Carriers or collectors characterised by shape or form
    • H01M4/80—Porous plates, e.g. sintered carriers
    • H01M4/808—Foamed, spongy materials
    • H—ELECTRICITY
    • H01—ELECTRIC ELEMENTS
    • H01M—PROCESSES OR MEANS, e.g. BATTERIES, FOR THE DIRECT CONVERSION OF CHEMICAL ENERGY INTO ELECTRICAL ENERGY
    • H01M50/00—Constructional details or processes of manufacture of the non-active parts of electrochemical cells other than fuel cells, e.g. hybrid cells
    • H01M50/10—Primary casings; Jackets or wrappings
    • H01M50/102—Primary casings; Jackets or wrappings characterised by their shape or physical structure
    • H01M50/103—Primary casings; Jackets or wrappings characterised by their shape or physical structure prismatic or rectangular
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02E—REDUCTION OF GREENHOUSE GAS [GHG] EMISSIONS, RELATED TO ENERGY GENERATION, TRANSMISSION OR DISTRIBUTION
    • Y02E60/00—Enabling technologies; Technologies with a potential or indirect contribution to GHG emissions mitigation
    • Y02E60/10—Energy storage using batteries

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Electrochemistry (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Manufacturing & Machinery (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
DK97904133T 1996-02-13 1997-02-12 Kombinationer med immunoundertrykkende virkninger indeholdende cyclooxygenase-2-inhibitorer og 5-lipooxygenaseinhibitortorer DK0888127T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US60062296A 1996-02-13 1996-02-13
PCT/US1997/001558 WO1997029776A1 (en) 1996-02-13 1997-02-12 Combinations having immunosuppressive effects, containing cyclooxygenase-2-inhibitors and 5-lipoxygenase inhibitors

Publications (1)

Publication Number Publication Date
DK0888127T3 true DK0888127T3 (da) 2002-04-08

Family

ID=24404352

Family Applications (1)

Application Number Title Priority Date Filing Date
DK97904133T DK0888127T3 (da) 1996-02-13 1997-02-12 Kombinationer med immunoundertrykkende virkninger indeholdende cyclooxygenase-2-inhibitorer og 5-lipooxygenaseinhibitortorer

Country Status (11)

Country Link
US (2) US6376528B1 (da)
EP (1) EP0888127B1 (da)
JP (1) JP2000504723A (da)
AT (1) ATE210461T1 (da)
AU (1) AU1850597A (da)
CA (1) CA2246265A1 (da)
DE (1) DE69709069T2 (da)
DK (1) DK0888127T3 (da)
ES (1) ES2169351T3 (da)
PT (1) PT888127E (da)
WO (1) WO1997029776A1 (da)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6512121B2 (en) 1998-09-14 2003-01-28 G.D. Searle & Co. Heterocyclo substituted hydroxamic acid derivatives as cyclooxygenase-2 and 5-lipoxygenase inhibitors
ES2169351T3 (es) 1996-02-13 2002-07-01 Searle & Co Combinaciones que tienen efectos inmunosupresores, que contienen inhibidores de ciclooxigenasa-2 y 5-lipoxigenasa.
US6218437B1 (en) 1996-09-30 2001-04-17 The Regents Of The University Of California Treatment and prevention of hepatic disorders
CA2313049A1 (en) * 1997-12-17 1999-06-24 Cornell Research Foundation, Inc. Cyclooxygenase-2 inhibition
US7041694B1 (en) * 1997-12-17 2006-05-09 Cornell Research Foundation, Inc. Cyclooxygenase-2 inhibition
US6194431B1 (en) 1998-04-14 2001-02-27 Paul D. Rubin Methods and compositions using terfenadine metabolites in combination with leukotriene inhibitors
DE60038118T2 (de) * 1999-07-12 2009-03-05 Sandoz Ag Formulierungen von wachstumshormonen
AU2001261409A1 (en) * 2000-05-11 2001-11-20 Oklahoma Medical Research Foundation Prevention of insulin-dependent diabetes, complications thereof, or allograft rejection by inhibition of cyclooxygenase-2 activity with NS398 or PDTC
US20020035107A1 (en) 2000-06-20 2002-03-21 Stefan Henke Highly concentrated stable meloxicam solutions
DE10121252A1 (de) * 2001-04-30 2002-11-07 Christos C Zouboulis Behandlung der Akne
AR038957A1 (es) 2001-08-15 2005-02-02 Pharmacia Corp Terapia de combinacion para el tratamiento del cancer
DE10161077A1 (de) 2001-12-12 2003-06-18 Boehringer Ingelheim Vetmed Hochkonzentrierte stabile Meloxicamlösungen zur nadellosen Injektion
MXPA04010927A (es) * 2002-05-02 2006-01-30 Univ Washington Metodos y composiciones para el tratamiento de enfermedades y trastornos inflamatorios/autoinmunes producidos por linfocitos t en sujetos que padecen una deficiencia en la regulacion de glucocorticoides.
DE10223013A1 (de) * 2002-05-22 2003-12-04 Boehringer Ingelheim Int Verwendung von Meloxicam für die Linderung von Organverletzungen während Organoperation oder -transplantation
US8992980B2 (en) 2002-10-25 2015-03-31 Boehringer Ingelheim Vetmedica Gmbh Water-soluble meloxicam granules
ES2275218T3 (es) 2003-05-07 2007-06-01 Osteologix A/S Sales de estroncio hidrosolubles para el tratamiento de afecciones de cartilagos y/o huesos.
DE10351035A1 (de) * 2003-10-31 2005-05-25 Merckle Gmbh Chemisch Pharmazeutische Fabrik Pharmazeutische Licofelone-Formulierung
US20050129764A1 (en) * 2003-12-11 2005-06-16 Vergez Juan A. Osmotic device containing licofelone
US20050159470A1 (en) * 2003-12-19 2005-07-21 Syrrx, Inc. Histone deacetylase inhibitors
WO2005079419A2 (en) * 2004-02-17 2005-09-01 The Regents Of The University Of California Methods of treating immunopathological disorders
EP1568369A1 (en) 2004-02-23 2005-08-31 Boehringer Ingelheim Vetmedica Gmbh Use of meloxicam for the treatment of respiratory diseases in pigs
WO2005123130A2 (en) * 2004-06-17 2005-12-29 Osteologix A/S Improved treatments of rheumatic and arthritic diseases comprising combinations of a 5-lipoxygenase inhibitor
DE102005012971A1 (de) * 2005-03-21 2006-09-28 Merckle Gmbh Polymorphe Form von 6-(4-Chlorphenyl)-2,2-dimethyl-7-phenyl-2,3-dihydro-1H-pyrrolizin-5-yl-essigsäure
CA2622642C (en) 2005-09-16 2013-12-31 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
TW200838536A (en) 2006-11-29 2008-10-01 Takeda Pharmaceutical Polymorphs of succinate salt of 2-[6-(3-amino-piperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-ylmethy]-4-fluor-benzonitrile and methods of use therefor
US20100221334A1 (en) * 2007-07-19 2010-09-02 Fink Mitchell P Compositions including leukotriene antagonists and nsaids and methods of using the same
US11033523B2 (en) 2009-04-29 2021-06-15 Amarin Pharmaceuticals Ireland Limited Pharmaceutical compositions comprising EPA and a cardiovascular agent and methods of using the same
MX2012004177A (es) 2009-10-12 2012-05-08 Boehringer Ingelheim Vetmed Recipiente para composiciones que comprenden meloxicam.
SG183846A1 (en) 2010-03-03 2012-10-30 Boehringer Ingelheim Vetmed Use of meloxicam for the long-term treatment of musculoskeletal disorders in cats
US9795568B2 (en) 2010-05-05 2017-10-24 Boehringer Ingelheim Vetmedica Gmbh Low concentration meloxicam tablets
US9161894B2 (en) 2011-03-01 2015-10-20 Npharmakon, Llc Use of N-(4-methoxyphenyl)-1-phenyl-1H-pyrazol-3-amine and related compounds
CA2906145A1 (en) 2013-03-15 2014-09-18 Edison Pharmaceuticals, Inc. Alkyl-heteroaryl substituted quinone derivatives for treatment of oxidative stress disorders
WO2015077905A1 (en) 2013-11-29 2015-06-04 Merck Sharp & Dohme Corp. Bicycloamine-substituted-n-benzenesulfonamide compounds with selective activity in voltage-gated sodium channels
EP3484464B1 (en) * 2016-03-22 2020-10-28 Merck Sharp & Dohme Corp. N1-phenylpropane-1,2-diamine compounds with selective activity in voltage-gated sodium channels

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS59196839A (ja) 1983-04-21 1984-11-08 Sankyo Co Ltd フエニル酢酸誘導体
US4686231A (en) 1985-12-12 1987-08-11 Smithkline Beckman Corporation Inhibition of 5-lipoxygenase products
US4873259A (en) 1987-06-10 1989-10-10 Abbott Laboratories Indole, benzofuran, benzothiophene containing lipoxygenase inhibiting compounds
US5242940A (en) 1987-05-29 1993-09-07 Ortho Pharmaceutical Corporation Pharmacologically active N-1 and C-5 heterocyclic pyrazoles and method for synthesizing the same
KR920003601B1 (ko) 1987-09-03 1992-05-04 유니버시티 어브 죠지아 리서취 화운데이션 인코포레이티드 점안 싸이클로스포린(cyclosporin)의 조성물
US4889935A (en) 1987-12-18 1989-12-26 American Home Products Corporation Aminoguanidine derivatives
GB8927287D0 (en) 1988-12-23 1990-01-31 Ici Plc Cyclic ether derivatives
US5234950A (en) 1988-12-23 1993-08-10 Imperial Chemical Industries Plc Tetrahydrofuran derivatives
US5220059A (en) 1990-04-19 1993-06-15 Abbott Laboratories Lipoxygenase-inhibiting compounds derived from non-steroidal antiinflammatory carboxylic acids
ATE144247T1 (de) 1990-07-25 1996-11-15 Abbott Lab Acetylenderivate mit lipoxygenase inhibitorischer wirkung
IE913655A1 (en) * 1990-11-06 1992-05-22 Zeneca Ltd Synergistic agents
EP0569493A4 (en) 1991-01-31 1993-11-24 Warner-Lambert Company Substituted 4,6-di-tertiary-butyl-5-hydroxy-pyrimidines
DE69206725T2 (de) 1991-09-10 1996-05-02 Zeneca Ltd Benzolsulfonamidderivate als 5-Lipoxygenasehemmer
US5272178A (en) 1991-11-18 1993-12-21 G. D. Searle & Co. Compounds of cyclic phenolic thioethers which are useful in stimulating and inhibiting superoxide generation
GB9215921D0 (en) 1992-07-27 1992-09-09 Wellcome Found Anti-inflammatory compounds
US5354865A (en) 1992-09-10 1994-10-11 Abbott Laboratories Phenylmethyl derivatives having lipoxygenase inhibitory activity
US5288751A (en) 1992-11-06 1994-02-22 Abbott Laboratories [(Substituted) phenyalkyl]furylalkynyl-and [substituted) phenyalkyl] thienylalkynyl-N-hydroxyurea inhibitors or leukotriene biosynthesis
US5604260A (en) 1992-12-11 1997-02-18 Merck Frosst Canada Inc. 5-methanesulfonamido-1-indanones as an inhibitor of cyclooxygenase-2
CA2152792C (en) 1993-01-15 2000-02-15 Stephen R. Bertenshaw Novel 3,4-diaryl thiophenes and analogs thereof having use as antiinflammatory agents
US5409944A (en) 1993-03-12 1995-04-25 Merck Frosst Canada, Inc. Alkanesulfonamido-1-indanone derivatives as inhibitors of cyclooxygenase
CA2161789A1 (en) 1993-05-13 1994-11-24 Jacques Yves Gauthier 2-substituted-3,4-diarylthiophene derivatives as inhibitors of cyclooxygenase
US5380738A (en) 1993-05-21 1995-01-10 Monsanto Company 2-substituted oxazoles further substituted by 4-fluorophenyl and 4-methylsulfonylphenyl as antiinflammatory agents
US5474995A (en) 1993-06-24 1995-12-12 Merck Frosst Canada, Inc. Phenyl heterocycles as cox-2 inhibitors
US5298521A (en) 1993-08-30 1994-03-29 Ortho Pharmaceutical Corporation 1,5-diphenyl-3-pyrazolylalkyl-N-hydroxydithiocaramates, compositions and use
US5344991A (en) 1993-10-29 1994-09-06 G.D. Searle & Co. 1,2 diarylcyclopentenyl compounds for the treatment of inflammation
CN1061036C (zh) 1993-11-30 2001-01-24 G·D·瑟尔公司 用于治疗炎症的取代的吡唑基苯磺酰胺类化合物
US5393790A (en) 1994-02-10 1995-02-28 G.D. Searle & Co. Substituted spiro compounds for the treatment of inflammation
US5486534A (en) * 1994-07-21 1996-01-23 G. D. Searle & Co. 3,4-substituted pyrazoles for the treatment of inflammation
WO1996025405A1 (en) * 1995-02-13 1996-08-22 G.D. Searle & Co. Substituted isoxazoles for the treatment of inflammation
CA2223154A1 (en) 1995-06-02 1996-12-05 G.D. Searle & Co. Heterocyclo substituted hydroxamic acid derivatives as cyclooxygenase-2 and 5-lipoxygenase inhibitors
US5643933A (en) 1995-06-02 1997-07-01 G. D. Searle & Co. Substituted sulfonylphenylheterocycles as cyclooxygenase-2 and 5-lipoxygenase inhibitors
US5700816A (en) 1995-06-12 1997-12-23 Isakson; Peter C. Treatment of inflammation and inflammation-related disorders with a combination of a cyclooxygenase-2 inhibitor and a leukotriene A4 hydrolase inhibitor
JPH11507670A (ja) * 1995-06-12 1999-07-06 ジー．ディー．サール アンド カンパニー シクロオキシゲナーゼ−２インヒビターと５−リポキシゲナーゼインヒビターの組合せによる炎症と炎症関連疾患の治療
ATE296114T1 (de) 1996-02-13 2005-06-15 Searle & Co Zubereitungen, enthaltend einen cyclooxygenase-2- inhibitor und einen leukotrien-b4-rezeptor- antagonisten
ES2169351T3 (es) 1996-02-13 2002-07-01 Searle & Co Combinaciones que tienen efectos inmunosupresores, que contienen inhibidores de ciclooxigenasa-2 y 5-lipoxigenasa.
DK0880363T3 (da) * 1996-02-13 2003-01-20 Searle & Co Kombinationer der omfatter en cyclooxygenase-2 hæmmer samt en leukotrien A4 hydrolasehæmmer, som har immunsuppressive virkninger
US5919776A (en) * 1996-12-20 1999-07-06 Merck & Co., Inc. Substituted aminoquinolines as modulators of chemokine receptor activity
US6013644A (en) * 1997-12-12 2000-01-11 Merck & Co., Inc. Spiro-substituted azacycles as modulators of chemokine receptor activity
US6500844B1 (en) * 1999-06-11 2002-12-31 Merck & Co., Inc. Cyclopentyl modulators of chemokine receptor activity

Also Published As

Publication number Publication date
DE69709069D1 (de) 2002-01-24
US20020143033A1 (en) 2002-10-03
JP2000504723A (ja) 2000-04-18
EP0888127A1 (en) 1999-01-07
WO1997029776A1 (en) 1997-08-21
EP0888127B1 (en) 2001-12-12
PT888127E (pt) 2002-05-31
ES2169351T3 (es) 2002-07-01
AU1850597A (en) 1997-09-02
ATE210461T1 (de) 2001-12-15
US6376528B1 (en) 2002-04-23
DE69709069T2 (de) 2002-07-04
US7132441B2 (en) 2006-11-07
CA2246265A1 (en) 1997-08-21

Similar Documents

Publication Publication Date Title
DK0888127T3 (da) Kombinationer med immunoundertrykkende virkninger indeholdende cyclooxygenase-2-inhibitorer og 5-lipooxygenaseinhibitortorer
TNSN00010A1 (fr) DIPHENYLUREE A SUBSTITUTION ω CARBOXYARYLE SERVANT D'INHIBUTEURS DE RAF KINASE.
PA8523901A1 (es) Composiciones farmaceuticas de inhibidores de la proteina de transferencia de colesteril ester
ES2196190T3 (es) Inhibidores de metaloproteinasas matriciales, con hidroxamato bifenlico.
DE60033316D1 (de) Tricyclische proteinkinasehemmer
DE69322289D1 (de) Behandlung von entzündlichen darmerkrankungen mit interferon-gamma-inhibitoren
DE69840025D1 (de) Assoziierter antworten
TR200000815T2 (tr) In vitro hematopoietik hücrelerin stimulasyonu.
ES1053994U (es) Elemento interior para cajones.
YU53899A (sh) Primena inhibitora ciklooksigenaze-2 u prevenciji kardiovaskularnih poremećaja
SE9604793D0 (sv) New polymorphs
ATE474597T1 (de) Inhibition des migrations-inhibitions-faktors in der behandlung von krankheiten bei denen eine cytokin-vermittelte toxizität eine rolle spielt
CY1109462T1 (el) Συνθεση και διαδικασια εκχυλιση του διαλυτη μεταλλων χρησιμοποιωντας τους παραγοντες εκχυλισης αλδοξιμη ή κετοξιμη
NO20004799L (no) Anvendelse av cabergolin ved behandling av urolig bensyndrom
DE69512930T2 (de) Stilben-derivate verwendbar als cyclooxygenase-2 hemmer
DK0705100T3 (da) Terapeutiske substituerede guanidiner
ES2183140T3 (es) Combinaciones, que tienen efectos inmunosupresores, que contienen un inhibidor de ciclooxigenasa-2 y un inhibidor de leucotrieno a4 hidrolasa.
TR200202030T2 (tr) IL-18 inhibitörlerinin kullanımı.
HK1064950A1 (en) Methods for treating or preventing vascular inflammation using sterol absorption inhibitor(s)
DK0801572T3 (da) Sammensætning til inhibering af intimal hyperplasi ved anvendelse af PDGF-antagonister og heparin
ATE414510T1 (de) Verwendung von 13-hode als regulator der vaskulären biokompatibilität und als inhibitor der zellulären hyperplasie
TR199901703T2 (xx) Siklooksijenaz-2 inhibit�rlerini anti-anjiyojenik ajanlar olarak kullanma y�ntemi.
DK1147420T3 (da) Urintrypsininhibitor til diagnosticering af AIDS
ITRM920491A0 (it) Immunodosaggio di enzima b12 e procedimento di trattamento di campioniper esso.
PT906268E (pt) Fluorenonas com substituicao alquiloxiamino e sua utilizacao como inibidores da proteina quinase c